Bayer and CureVac to collaborate on COVID-19 vaccine candidate

pharmafile | January 8, 2021 | News story | Medical Communications Bayer, COVID-19, Vaccine 

Bayer is joining forces with CureVac, a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), on its COVID-19 vaccine candidate CVnCoV.

Under the parties’ collaboration and services agreement, Bayer will support the further development, supply, and key territory operations of CureVac´s coronavirus jab.

CureVac commenced Phase IIb/III trials for its vaccine candidate last month, after ramping up its European manufacturing network in November.

CureVac will be the Marketing Authorisation Holder for the product. Bayer will support CureVac with country operations within the EU and selected additional markets, but holds further options to become Marketing Authorisation Holder in other markets outside of Europe.

The companies plan to supply hundreds of millions of CVnCoV doses globally once approvals are granted.

Stefan Oelrich, Member of the Board of Management at Bayer and President of the Bayer’s Pharmaceuticals Division, said: “The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate.

“We are highly committed to making our capabilities and networks available to help end this pandemic.”

Darcy Jimenez

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

Latest content